论文部分内容阅读
目的:探讨结肠癌激酶4(CCK4)的表达与卵巢癌临床病理特征的关系。方法:采用免疫组织化学MaxVision法检测CCK4在卵巢性索间质肿瘤,卵巢生殖细胞肿瘤、卵巢交界性肿瘤、卵巢上皮性癌组织中的表达。结果:与良性卵巢肿瘤相比,卵巢上皮性癌、卵巢交界性肿瘤、卵巢性索间质肿瘤,卵巢生殖细胞肿瘤明显低表达,差异有统计学意义(P<0.05)。与卵巢交界性肿瘤相比,卵巢上皮性癌CCK4表达减少,但差异无统计学意义(P>0.05)。在卵巢上皮性癌中,与年龄<50岁组相比,年龄≥50组卵巢上皮性癌表达减少,但差异无统计学意义(P>0.05);与临床分期Ⅰ~Ⅱ期组相比,临床分期Ⅲ~Ⅳ期组卵巢上皮性癌明显低表达,差异有统计学意义(P<0.05);与无腹膜转移组相比,有腹膜转移组卵巢上皮性癌明显低表达,差异有统计学意义(P<0.05)。结论:CCK4低表达与卵巢癌的腹膜转移密切相关,有可能是治疗卵巢癌的重要靶点之一。
Objective: To investigate the relationship between the expression of CCK4 and the clinicopathological features of ovarian cancer. Methods: The expression of CCK4 in ovarian sex cord tumor, ovarian germ cell tumor, borderline ovarian tumor and ovarian epithelial carcinoma was detected by immunohistochemistry MaxVision method. Results: Compared with benign ovarian tumors, ovarian epithelial carcinoma, borderline ovarian tumors, ovarian prominence stromal tumors and ovarian germ cell tumors were significantly lower (P <0.05). Compared with the borderline ovarian tumors, the expression of CCK4 in ovarian epithelial carcinoma decreased, but the difference was not statistically significant (P> 0.05). In ovarian epithelial carcinoma, the expression of epithelial ovarian cancer in the group of≥50 years old was lower than that in the group <50 years old, but the difference was not statistically significant (P> 0.05); Compared with the clinical staging Ⅰ ~ Ⅱ group, The clinical stages Ⅲ ~ Ⅳ group ovarian epithelial carcinoma was significantly lower expression, the difference was statistically significant (P <0.05); compared with no peritoneal metastasis group, peritoneal metastasis ovarian epithelial carcinoma was significantly lower, the difference was statistically significant Significance (P <0.05). Conclusion: The low expression of CCK4 is closely related to peritoneal metastasis of ovarian cancer, which may be one of the important targets for the treatment of ovarian cancer.